Heat-shock protein vaccines using conjugated tumor peptides [124,125] and direct HSP90 inhibitors such as 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) [76] have been investigated in clinical trials. This evidence concerns the gene HSP90AA1 and neoplasm.